Nuclear access
Help therapeutic DNA reach the nucleus using delivery designs that are compatible with the cell’s internal transport architecture.
Inlet Bio
Programmable delivery through cellular architecture.
Inlet Bio is building a nonviral genetic-medicine platform designed to move therapeutic DNA through cellular barriers, reach the nucleus, and support durable activity without viral capsids or genome integration.
The bottleneck
DNA medicines need better delivery and durability.
Genetic medicines can be designed quickly, but delivery remains the central challenge. For durable DNA-based therapies, the payload must do more than enter a cell. It must survive transit, reach the right intracellular compartment, remain active, and avoid triggering excessive innate immune alarm.
Inlet Bio is focused on making nonviral DNA delivery more programmable, durable, and redosable.
Platform thesis
Delivery engineered around cellular architecture.
The platform is built around three high-level design layers that address the major intracellular barriers for nonviral DNA medicines.
Durable episomal activity
Support useful expression from non-integrating DNA that remains outside the genome.
Immune-aware delivery
Design payloads and particles to reduce unnecessary inflammatory sensing and support repeat administration.
What makes it different
A systems view of nonviral delivery.
Rather than optimizing the DNA sequence, particle, or immune profile in isolation, Inlet Bio treats delivery as a linked system.
Move
Design the payload-particle system to move through key cellular barriers.
Arrive
Support localization, where DNA can be most active.
Remain active
Support durable activity without relying on viral capsids or genome integration.
Stay quiet
Balance activity with immune tolerability to support practical therapeutic dosing.
Program focus
Three candidate asset lanes.
Inlet Bio is organizing its platform around three product directions where durable, redosable, nonviral DNA delivery could matter most.
A
Secreted protein replacement
Programs designed to help target tissues produce useful therapeutic proteins over time.
B
Local tissue delivery
Programs for accessible tissues where repeat local dosing and immune tolerability are important.
C
Cell-based applications
Programs for cells handled outside the body, where delivery, activity, and cell health can be measured before use.
Contact
Connect with Inlet Bio.
For partnering, scientific, or company inquiries, please reach out by email.
info@inletbio.com867 Boylston St
Suite 500 Unit #1482
Boston, MA 02116